Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
Open Access
- 1 August 2022
- journal article
- research article
- Published by Springer Nature in Animal Diseases
- Vol. 2 (1) , 1-15
Abstract
Natural killer T (NKT) cells activated with the glycolipid ligand α-galactosylceramide (α-GalCer) stimulate a wide variety of immune cells that enhance vaccine-mediated immune responses. Several studies have used this approach to adjuvant inactivated and subunit influenza A virus (IAV) vaccines, including to enhance cross-protective influenza immunity. However, less is known about whether α-GalCer can enhance live attenuated influenza virus (LAIV) vaccines, which usually induce superior heterologous and heterosubtypic immunity compared to non-replicating influenza vaccines. The current study used the swine influenza challenge model to assess whether α-GalCer can enhance cross-protective immune responses elicited by a recombinant H3N2 LAIV vaccine (TX98ΔNS1) encoding a truncated NS1 protein. In one study, weaning pigs were administered the H3N2 TX98ΔNS1 LAIV vaccine with 0, 10, 50, and 100 μg/kg doses of α-GalCer, and subsequently challenged with a heterologous H3N2 virus. All treatment groups were protected from infection. However, the addition of α-GalCer appeared to suppress nasal shedding of the LAIV vaccine. In another experiment, pigs vaccinated with the H3N2 LAIV, with or without 50 μg/kg of α-GalCer, were challenged with the heterosubtypic pandemic H1N1 virus. Pigs vaccinated with the LAIV alone generated cross-reactive humoral and cellular responses which blocked virus replication in the airways, and significantly decreased virus shedding. On the other hand, combining the vaccine with α-GalCer reduced cross-protective cellular and antibody responses, and resulted in higher virus titers in respiratory tissues. These findings suggest that: (i) high doses of α-GalCer impair the replication and nasal shedding of the LAIV vaccine; and (ii) α-GalCer might interfere with heterosubtypic cross-protective immune responses. This research raise concerns that should be considered before trying to use NKT cell agonists as a possible adjuvant approach for LAIV vaccines.Keywords
Funding Information
- National Institute of Child Health and Human Development (HD092286, HD092286)
- National Institute of Food and Agriculture (2016-09448)
- National Institute of Allergy and Infectious Diseases (HHSN272201400006C)
- U.S. Department of Homeland Security (DHS-2010-ST-061-AG0001)
This publication has 57 references indexed in Scilit:
- Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysisBMC Medicine, 2013
- A distinct lineage of influenza A virus from batsProceedings of the National Academy of Sciences, 2012
- Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young ChildrenThe Journal of Infectious Diseases, 2011
- Invariant natural killer T cells: bridging innate and adaptive immunityCell and tissue research, 2010
- Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvantProceedings of the National Academy of Sciences, 2010
- Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccineVaccine, 2009
- Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swineVaccine, 2007
- Vaccination of Pigs against Swine Influenza Viruses by Using an NS1-Truncated Modified Live-Virus VaccineJournal of Virology, 2006
- Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of miceProceedings of the National Academy of Sciences, 2006
- Influenza Virus Evades Innate and Adaptive Immunity via the NS1 ProteinJournal of Virology, 2006